# Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac

> **NCT03878004** · PHASE2 · COMPLETED · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 180 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** GamTBvac vaccine
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT03878004
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2020-06-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03878004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03878004, "Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03878004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*